Role of sentinel lymph node biopsy in determination of extent of surgery for cutaneous melanoma

Cover Page

Cite item

Full Text

Abstract

Introduction. Cutaneous melanoma is a malignant tumor of neuroectodermal origin developing from melanocytes (pigment cells) of the skin. It is characterized by aggressive growth, high risk of metastasis and progression.

Aim. Retrospective study of outcomes of surgical treatment of cutaneous melanoma with biopsy of the sentinel lymph node and subsequent intervention on regional lymph nodes/observation and evaluation of risk factors of disease progression.

 Materials and methods. Retrospective cohort study was performed at the Nizhny Novgorod Regional Clinical Oncological Dispensary. The study included patients with cutaneous melanoma who underwent surgical treatment with biopsy of the sentinel lymph node.

 Results. Risk factors for disease progression were analyzed, and the unfavorable prognostic value of the thickness  and presence of ulceration of the primary tumor, the presence of melanoma metastases in the sentinel lymph node,  as well as the age of patients and the driver mutation of the tumor were demonstrated. Lymphadenectomy performed after a biopsy of the signaling lymph node and the localization of the tumor had no effect on the disease outcome.

About the authors

A. I.  Lomteva

Nizhny  Novgorod  Regional  Clinical  Oncological  Dispensary

Author for correspondence.
Email: anastasia.andreeva1997@mail.ru

Anastasiya Igorevna Lomteva

11/1  Delovaya  St.,  Nizhny  Novgorod  603163

Russian Federation

A. P.  Bavrina

Volga  Region  Medical  Research  University,  Ministry  of  Health  of  Russia

10/1  Minina  and  Pozharskogo  Ploshchad,  Nizhny  Novgorod  603005

Russian Federation

V. V. Radovsky

Nizhny  Novgorod  Regional  Clinical  Oncological  Dispensary

11/1  Delovaya  St.,  Nizhny  Novgorod  603163

Russian Federation

D.  S.  Myalik

Nizhny  Novgorod  Regional  Clinical  Oncological  Dispensary

11/1  Delovaya  St.,  Nizhny  Novgorod  603163

Russian Federation

T.  V. Burova

Nizhny  Novgorod  Regional  Clinical  Oncological  Dispensary

11/1  Delovaya  St.,  Nizhny  Novgorod  603163

Russian Federation

B. A. Davlatov

Nizhny  Novgorod  Regional  Clinical  Oncological  Dispensary; Volga  Region  Medical  Research  University,  Ministry  of  Health  of  Russia

11/1  Delovaya  St.,  Nizhny  Novgorod  603163

10/1  Minina  and  Pozharskogo  Ploshchad,  Nizhny  Novgorod  603005

Russian Federation

A. Yu. Vorontsov

Nizhny  Novgorod  Regional  Clinical  Oncological  Dispensary

ORCID iD: 0000-0002-3657-5274

11/1  Delovaya  St.,  Nizhny  Novgorod  603163

Russian Federation

S. V. Gamayunov

Nizhny  Novgorod  Regional  Clinical  Oncological  Dispensary; Volga  Region  Medical  Research  University,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0002-0223-0753

11/1  Delovaya  St.,  Nizhny  Novgorod  603163

10/1  Minina  and  Pozharskogo  Ploshchad,  Nizhny  Novgorod  603005

Russian Federation

A. V. Maslennikova

Nizhny  Novgorod  Regional  Clinical  Oncological  Dispensary; Volga  Region  Medical  Research  University,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0003-0434-4372

11/1  Delovaya  St.,  Nizhny  Novgorod  603163

10/1  Minina  and  Pozharskogo  Ploshchad,  Nizhny  Novgorod  603005

Russian Federation

References

  1. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).
  2. Wong S.L., Balch C.M., Hurley P. et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012;30(23):2912–8. doi: 10.1200/JCO.2011.40.3519
  3. Zettersten E., Sagebiel R.W., Miller J.R. 3rd et al. Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer 2002;94(4):1049–56.
  4. Cutaneous and mucosal melanoma. Clinical guidelines. Association of Specialists on Melanoma Problems, Association of Oncologists of Russia, Russian Society of Children’s Oncologists and Hematologists, Russian Society of Clinical Oncology. Moscow: 2025, 210 p. Available at: https://cr.minzdrav.gov.ru/preview-cr/921_1 (In Russ.).
  5. Braithwaite L. The flow of lymph from the ileocæcal angle, and its possible bearing on the cause of duodenal and gastric ulcer. Br J Surg 2005;11(41):7–26. doi: 10.1002/bjs.1800114103
  6. Hodges M., Jones E., Jones T. et al. Analysis of melanoma recurrence following a negative sentinel lymph node biopsy. Melanoma Manag 2015;2(3):285–94. doi: 10.2217/mmt.15.19
  7. McMasters K.M., Reintgen D.S., Ross M.I. et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001;19(11):2851–5. doi: 10.1200/JCO.2001.19.11.2851
  8. Morton D.L., Thompson J.F., Cochran A.J. e al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370(7):599–609. doi: 10.1056/NEJMoa1310460
  9. Leiter U., Stadler R., Mauch C. et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 2016;17(6):757–67. doi: 10.1016/S1470-2045(16)00141-8
  10. Faries M.B., Thompson J.F., Cochran A.J. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017;376(23):2211–22. doi: 10.1056/NEJMoa1613210
  11. Baecher H., Gerken M., Knoedler L. et al. Complete lymph node dissection in cutaneous melanoma patients with positive sentinel lymph node: outcome and predictors in a retrospective cohort study over 16 years. J Plast Reconstr Aesthet Surg 2024;92:33–47. doi: 10.1016/j.bjps.2024.02.056
  12. Rughani M.G., Swan M.C., Adams T.S. et al. Sentinel lymph node biopsy in melanoma: the Oxford ten year clinical experience. J Plast Reconstr Aesthet Surg 2011;64(10):1284–90. doi: 10.1016/j.bjps.2011.05.001
  13. Nowecki Z.I., Rutkowski P., Nasierowska-Guttmejer A., Ruka W. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes – one institution’s experience. Melanoma Res 2003;13(1):35–43. doi: 10.1097/00008390-200302000-00007
  14. Susok L., Nick C., Becker J.C. Waiving subsequent complete lymph node dissection in melanoma patients with positive sentinel lymph node does not result in worse outcome on 20-year analysis. Cancers (Basel) 2021;13(21):5425. doi: 10.3390/cancers13215425
  15. Ziętek M., Teterycz P., Wierzbicki J. et al. The current treatment trends and survival patterns in melanoma patients with positive sentinel lymph node biopsy (SLNB): a multicenter nationwide study. Cancers (Basel) 2023;15(10):2667. doi: 10.3390/cancers15102667
  16. Zhong J., Zou Z., Hu T. et al. Survival impact of immediate complete lymph node dissection for Chinese acral and cutaneous melanoma with micrometastasis in sentinel nodes: a retrospective study. Clin Exp Med 2023;23(7):4003–10. doi: 10.1007/s10238-023-01107-z
  17. Al-Qurayshi Z., Hassan M., Srivastav S. et al. Risk and survival of patients with head and neck cutaneous melanoma: national perspective. Oncology 2017;93(1):18–28. doi: 10.1159/000458530
  18. Tseng W.H., Martinez S.R. Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res 2011;167(2):192–8. doi: 10.1016/j.jss.2010.10.008

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Lomteva A.I., Bavrina A.P., Radovsky V.V., Myalik D.S., Burova T.V., Davlatov B.A., Vorontsov A.Y., Gamayunov S.V., Maslennikova A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.